Abstract
Diabetic kidney disease is one of the most serious complications of type 2 diabetes and a leading cause of end-stage kidney disease. Recently, the Korean Diabetes Association released a new version of clinical practice guidelines including substantial changes in the management of diabetic kidney disease. Of note, sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists are now the preferred glucose-lowering agents for reduced glomerular filtration rate or albuminuria. Convincing evidence from cardiovascular or renal outcome trials supports the recommendation of those drugs. This review summarizes the results of recent clinical studies on diabetic kidney disease and explains new clinical recommendations based on them.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
